Abciximab indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Abciximab}} {{CMG}}; {{AE}} {{SS}}, {{PB}} ==Indications and Usage== Abciximab is indicated as an adjunct to percutaneous coronary intervention for the preve..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 19: | Line 19: | ||
{{FDA}} | {{FDA}} | ||
[[Category: | [[Category:Drugs]] | ||
Revision as of 19:43, 29 January 2014
Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2], Pratik Bahekar, MBBS [3]
Indications and Usage
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.
- In patients undergoing percutaneous coronary intervention
- In patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.
Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.[1]
References
Adapted from the FDA Package Insert.